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New Findings 
• What is the central question of this study? 
Type 2 diabetes is associated with a higher rate of ventricular arrhythmias compared to 
the non-diabetic population, but the associated myocardial gene expression changes are 
unknown; furthermore, it is also unknown if any changes are due to chronic 
hyperglycaemia or a consequence of structural changes. 
• What is the main finding and its importance? 
We found downregulation of left ventricular ERG gene expression and 
increased NCX1gene expression in humans with type 2 diabetes compared with control 
patients with comparable left ventricular hypertrophy and possible myocardial fibrosis. 
This was associated with QT interval prolongation. Diabetes and associated chronic 
hyperglycaemia may therefore promote ventricular arrhythmogenesis independently of 
structural changes. 
 
Abstract 
Type 2 diabetes is associated with a higher rate of ventricular arrhythmias, and this is 
hypothesized to be independent of coronary artery disease or hypertension. To investigate 
further, we compared changes in left ventricular myocardial gene expression in type 2 
diabetes patients with patients in a control group with left ventricular hypertrophy. Nine 
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control patients and seven patients with type 2 diabetes with aortic stenosis undergoing 
aortic valve replacement had standard ECGs, signal-averaged ECGs and echocardiograms 
before surgery. During surgery, a left ventricular biopsy was taken, and mRNA expressions 
for genes relevant to the cardiac action potential were estimated by RT-PCR. Mathematical 
modelling of the action potential and calcium transient was undertaken using the O'Hara–
Rudy model using scaled changes in gene expression. Echocardiography revealed similar 
values for left ventricular size, filling pressures and ejection fraction between groups. No 
difference was seen in positive signal-averaged ECGs between groups, but the standard 
ECG demonstrated a prolonged QT interval in the diabetes group. Gene expression 
of KCNH2 and KCNJ3 were lower in the diabetes group, 
whereas KCNJ2, KCNJ5 and SLC8A1 expression were higher. Modelling suggested that 
these changes would lead to prolongation of the action potential duration with generation of 
early after-depolarizations secondary to a reduction in density of the rapid delayed rectifier 
K+current and increased Na+–Ca2+ exchange current. These data suggest that diabetes 
leads to pro-arrythmogenic changes in myocardial gene expression independently of left 
ventricular hypertrophy or fibrosis in an elderly population 
Abbreviations. 2D, 2-dimensional; AP, action potential; BMI, body mass index; CACNA1c-
d, L-type voltage gated Ca2 channel α subunit 1c-d; CX40-43, connexin 40-43; EAD, early 
after-depolarisation; EF, ejection fraction; ERG, ether-à-go-go-related gene; DAD, delayed 
after depolarization: IFCC, international federation of clinical chemistry and laboratory 
medicine; HCN 1-4, Na+/K+ hyperpolarisation-activated cyclic nucleotide gated channel 1-4; 
ICaL, L type Ca2+ current; IF, funny current; IK,1, inward rectifying K+ current; Ik,ach , 
acetylcholine activated inward rectifying current; IK, r, rapid delayed rectifier K+ current; IK, ur, 
ultra-rapid delayed rectifier K+ current ; IK, s, slow delayed rectifier K+ current; INa, fast Na+ 
current; INa/Ca, Na+-Ca2+ calcium exchange current; ITi, late transient inward current; Ito-f, fast-
transient outward K+ current; Ito-s, slow transient outward K+ current; KChIP2, K+ voltage 
gated channel interacting protein 2; KCNA4-5, K+ voltage gated channel subfamily A 
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member 4 and 5; KCND2/3, K+ voltagegated channel subfamily D member 2-5; KCNJ2/-5, 
K+ voltage gated channel subfamily J member 2- 5; KCNQ1, K+ voltage gated channel 
subfamily Q member 1; LV, left ventricle; MAPSE, mitral annular longitudinal excursion; 
MRI, magnetic resonance imaging; NCX1, Na+-Ca2+ calcium exchanger; OCT, optimal 
cutting temperature compound; qPCR, quantitative polymerase chain reaction 
measurement; RYR2, ryanodine receptor 2; SAECG, signal averaged ECG; SCN5a, Na+ 
voltage gated channel subunit α5; SERCA2a, sarcoplasmic reticulum Ca2+-ATPase; T1, 
spin–lattice relaxation time 
 
 
Introduction 
Type 2 diabetes is becoming increasingly common worldwide and is associated with 
ischaemic heart disease and other macrovascular diseases. A cardiomyopathy related to 
chronic damage from hyperglycaemia has been described and termed ‘diabetic 
cardiomyopathy’(Miki et al., 2013). Higher rates of cardiac arrhythmias are observed in 
diabetes (Suarez et al., 2005) and specifically in type 2 diabetes (Panova & Korneva, 2006) 
compared to control patients without diabetes, both in patients with established coronary 
artery disease and in the general population (Movahed et al., 2007).  
The mechanisms predisposing to increased arrhythmogenesis in patients with type 2 
diabetes are complex but it does seem to be independent of coronary artery disease and 
cardiac ejection fraction (Junttila et al., 2010; Eranti et al., 2016). Suggested potential 
disease specific mechanisms from animal studies  include an abnormal responses to 
catecholamines (Frier et al., 2011), inhibition of the ERG channel (Zhang et al., 2006) or  
alterations in cardiac ryanodine receptor number/function, as a result of chronic 
hyperglycaemia (Yaras et al., 2005). In addition to effects of type 2 diabetes, the treatment of 
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this condition can potentially be arrhythmogenic, with hypoglycaemia as a result of treatment 
with insulin or sulfonylureas linked to arrhythmias (Lindstrom et al., 1992) and specifically  as 
sulfonylureas also have an effect on cardiac K+ channels (Brady & Terzic, 1998). In addition 
to pro-arrhythmic cellular and channel level changes, arrhythmogenic structural changes 
such as left ventricular hypertrophy (LVH) and myocardial fibrosis are common in type 2 
diabetes (Karagueuzian, 2011). Cardiac hypertrophy and fibrosis in the absence of 
hypertension or ischaemia, can be seen in other cardiac diseases such as valvular aortic 
stenosis (Weidemann et al., 2009).  
In this study, we measured the gene expression of key ion channels and associated 
molecules to investigate what changes may underpin the higher arrhythmic event rate in 
patients with type 2 diabetes and how, using mathematical modelling based on gene 
expression data the action potential may be affected. We undertook this study in patients 
with aortic stenosis, a condition which also causes LVH and myocardial fibrosis, to try and 
identify changes specific to diabetes. 
Methods 
Ethics approval 
The study was approved by the NHS Liverpool East Research Ethics Committee 
(11/NW/0290) and conducted in accordance with the principles established in the 
Declaration of Helsinki sixth version. The study was not registered in a research database 
and this is an exception to clause 35 of the Helsinki declaration.   All participants gave 
written informed consent. 
Study population 
Criteria for inclusion were patients over 18 years of age, male or post-menopausal female, 
with or without type 2 diabetes, undergoing aortic valve replacement for aortic stenosis 
(calculated aortic valve area of 1cm2 or less) with preserved left ventricular function defined 
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by European Society of Cardiology and an ejection fraction of over 50% (Nagueh et al., 
2009) at Liverpool Heart and Chest Hospital.   
Exclusion criteria were patients in atrial fibrillation, patients with type 1 diabetes, chronic renal 
impairment with an estimated glomerular filtration rate of less than 30ml/minute (Levey et al., 
1999), need for surgery in addition to the aortic valve replacement other than coronary artery 
grafting, other conditions which may cause LV impairment such as regurgitant valvular lesions 
graded moderate or more, thyroid dysfunction and excess alcohol consumption. 
Our control group had their available medical records reviewed for previous random blood 
sugar measurements and fasting samples. All patients in the control group had not had any 
abnormal fasting glucose measurements (>7.0mmol/L) or random samples over 11.0mmol/L 
with typical symptoms(American Diabetes Association, 2015). 
Patients had their height, weight and waist circumference measured, body mass index (BMI) 
calculated and patients with diabetes had their most recent glycated haemoglobin( HbA1c) 
recorded using the International Federation of Clinical Chemistry and Laboratory Medicine 
(IFCC) method(John et al., 2007). In addition, medications for each patient’s diabetes 
treatment and any cardiac specific medication was recorded. 
ECG assessment 
All patients had a standard 12 lead ECG and their QT interval measured using the Bazett 
formula (Luo et al.). All patients underwent signal averaged ECG monitoring (SAECG) 
following a 10-minute rest in the supine position using a MAC 500 machine (GE 
healthcare,Madison, WI,USA) prior to cardiac surgery.  Digital filtering was performed with a 
40-250HZ band pass bidirectional filter and averages were taken over 250 beats with 
maximum acceptable noise of 0.5µV. 
All ECGs were analysed for late potentials (Okin et al., 1995). 
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Echocardiography 
All patients underwent 2-dimensional (2D) echocardiography study prior to cardiac surgery 
using commercially available vivid Q, vivid 7 (GE healthcare, Hatfield, Hertfordshire, UK) and 
IE 9 (Phillips, Guilford, Surrey) systems and a 3.5 MHz transducer.  
Assessment of strain was made using offline software (EchoPAC, GE healthcare) and 
measurements were made in apical 2, 3 and 4 chamber for global longitudinal strain with 
values from each segment being averaged for a mean score. Circumferential and radial 
strain was measured using a mean score from 6 segments in the parasternal short axis at 
the mid wall level as previously described (Hung et al., 2010). 
Several studies have reported that myocardial fibrosis can associated with higher rates of 
arrhythmias(de Jong et al., 2011) and is widely reported in patients with diabetes (Picatoste 
et al., 2013) and when trying to allow for this potential confounder we have tried to match our 
experimental group to a control group reported to also exhibit signs of myocardial fibrosis 
(patients with aortic stenosis). Myocardial fibrosis can be assessed by cardiac MRI 
(magnetic resonance imaging) or histological examination, but there have been studies in 
aortic stenosis (Weidemann et al., 2009) and diabetes (Ng et al., 2012) looking at the 
correlation of 2D speckle tracking strain rate using echocardiography with fibrosis in patients 
with normal ejection fraction values. A global contrast-enhanced myocardial T1 mapping time 
(spin–lattice relaxation time) on MRI of less than 500ms has been shown to correlate with 
fibrosis(Iles et al., 2008) and a T1 mapping time of less than 500ms has been correlated with 
a global longitudinal strain of less than -18% using 2d speckle tracking echocardiography 
(Ng et al., 2012).  
Left ventricular biopsy 
Patients had a biopsy sample taken by a consultant cardiothoracic surgeon through the LV 
apex in the position normally used for transapical aortic valve implantation at the time of 
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aortic valve replacement surgery. The biopsy was performed using a single TRUCUT™ 
biopsy needle (Cardinal Health, Dublin, Ohio, USA) just prior to the insertion of cardioplegia 
solution. The sample was then taken and immediately placed in physiological Hartmann’s 
solution (Baxter Health, Berkshire, UK) before immediate transfer to the lab for processing. 
All samples were mounted in OCT (optimal cutting temperature compound, Tissue Tek, 
Fisher Scientific, Loughborough, UK) before flash freezing in liquid nitrogen. 
RNA isolation and quantitative polymerase chain reaction measurement (qPCR) 
Briefly, from frozen tissue, RNA was isolated using mirVana RNA isolation kit (Life 
Technologies, Paisley, UK) and then amplified to cDNA using high-capacity RNA to cDNA for 
quantitative PCR (Applied Biosystems, Warrington, UK). 
Quantitative PCR was performed using custom preloaded low-density Taqman array micro-
fluidic cards which contain multiple specific individual custom gene primer sequences and 
universal Mastermix II and a 7900HT fast real-time PCR system (all Applied Biosystems). 
Samples were run with one control sample with distilled water for every gene target run per 
card. Expression of the gene targets was referenced to an abundant abundant housekeeper 
gene, 18-S in this study. We chose 18-s as the housekeeper gene for this study based on 
previous experimental work(Sharma et al., 2004; Pérez et al., 2007) and preliminary animal 
data from a previous study performed within the department (Ashrafi et al., 2016).   Initial 
mRNA expression data was logarithmically transformed using the 2-ΔΔCT method as previously 
described (Livak & Schmittgen, 2001). 
The list of target genes analysed with their context sequences is listed below in Table 1: 
Gene  Gene name Context sequences 
18-S Eukaryotic 18-S CCATTGGAGGGCAAGTCTGGTGCCA 
ATP2A2 Cardiac Sarcoplasmic Reticulum Ca2+Activated- ATPase 
2a 
AGATGTCTGTCTGCAAGATGTTTAT 
CACNA1
C 
L-type Voltage-Gated Ca2+ Channel Alpha Subunit 1c ACCAATTCCAACCTGGAACGAGTGG 
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CACNA1
D 
L-type Voltage-Gated Ca2+ Channel Alpha Subunit 1d GAATGGAAACCATTTGACATATTTA 
HCN1 Hyperpolarisation Activated Gated K+ Channel 1 ATCAGTGGGAGGAGATCTTCCACAT 
HCN2 Hyperpolarisation Activated Gated K+ Channel 2 CCCTACAGTGACTTCAGATTTTACT 
HCN4 Hyperpolarisation Activated Gated K+ Channel 4 ATGATGGCTTATTACAGTGGCAATG 
KCNA4 K+ voltage-gated channel, shaker-related subfamily, 4 ATGGGAGGCTTGCTGAACATGGATA 
KCNA5 K+ voltage-gated channel, shaker-related subfamily, 5 TCTAACAGCCGATCCAGTTTAAATG 
KCND2 K+ voltage-gated channel, Shal-related subfamily, 2 CACAACCAGTCGCTCCAGCCTTAAT 
KCND3 K+ voltage-gated channel, Shal-related subfamily, 3 CTCTGGCTCTGAGGAGCTGATCGGG 
KCNH2 Human Ether Related a Go-Go CAGTTCTTTCCTCAAGGAGACTCCA 
KCNIP2 Kv channel-interacting protein 2 CCTGCGCCAGCAACAGGACATGTTC 
KCNJ2 K+ inwardly-rectifying channel, subfamily J, 2 AAGCTGCTCAAATCTCGGCAGACAC 
KCNJ3 K+ inwardly-rectifying channel, subfamily J, 3 GTGGAAGCCACAGGCATGACCTGCC 
KCNJ5 K+ inwardly-rectifying channel, subfamily J, 5 CACCCACATCTCACAGCTGCGGGAA 
KCNQ1 K+ voltage-gated channel, KQT-like subfamily, 1 CATTACTGCAGGCCACCTACTCATG 
RYR2 Ryanodine Receptor 2 CCCGCCAGACACGACCACGCCATCG 
SLC8A1 Na+-Ca2+ Exchanger TCACTGTCAGTGCTGGGGAAGATGA 
SCN5A Na+ Channel, Voltage-Gated Type Vα  TGAGAAAGTGTACCACATCTGTGTG 
   
   
Table 1: Gene targets and primer sequences 
Mathematical modelling of the action potential 
In this study we used the O’Hara-Rudy dynamic model (O'Hara et al., 2011), which is a math-
ematical model simulating the human ventricular myocyte action potential transmurally, to look 
at the effect of the changes in mRNA seen in the diabetes group. This model has been used 
in a wide variety of experiments and experimental conditions with good validation(Bartos et 
al., 2013). Using this model, channel conductance was scaled per the measured average ratio 
of mRNA between the control and the diabetes groups. In the control and the diabetes groups, 
the models were run for a 5-s period to obtain a stable state condition before a sequence of 
external stimulus pulses (with an amplitude of 0.8 nA, duration of 5 ms and frequency of 1 Hz) 
were applied, to evoke an action potential. To evaluate the relative role of each of the remod-
elled ion channels, simulations were also performed by looking at the change to each individ-
ual ion channel alone.  
Statistical analysis 
10 
 
Patient characteristics are shown as mean and 95% confidence intervals. Experimental data 
are reported as mean ± SD  .All single variable experimental work was analysed for 
significance using a Student’s unpaired t-test comparing the control group to the type 2 
diabetes group. As previously described multiple t-tests with a Benjamini-Hochberg false 
discovery rate correction (≤0.05) was used to assess the significance of the mRNA 
expression results (Tsay et al., 2015).  . Results were taken as being significant with a P 
value of ≤0.05.  
Results  
Patient characteristics 
A summary of patients recruited and their mean baseline information is shown in Table 2 
and there were no were no significant differences in baseline patient characteristics (P=ns). 
Patient medication breakdowns are shown in Table 3 with no significant difference in 
medications usage between groups for β-blockers, angiotensin blocking drugs (ACE/ARB) or 
statin use.  
 
Table 2: Patient characteristics 
Table 3: Patient medications 
  
ECG assessment 
Standard ECG assessment of the corrected QT intervals revealed a higher mean QT interval 
in the diabetes group (n=9) (467ms±2.32) compared with the control group(n=7) 
(451ms±5.26; P=0.011).  SAECG assessment of our 2 groups yielded 1 patient in each 
group with a positive SAECG for late potentials.  
Echocardiographic assessment 
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Our results show that both study groups were comparable in terms of traditional 
measurements of left ventricular function (ejection fraction (EF)) and left ventricular wall 
thickness (septal width). Both groups showed significant hypertrophy of the left ventricular 
septum when compared to reference values (Lang et al., 2005) and the left ventricular 
hypertrophy seen was felt to be due to pressure loading from the aortic stenosis and 
therefore by European society of cardiology guidance is appropriate and not suggestive of 
hypertrophic cardiomyopathy(Authors/Task Force et al., 2014). However longitudinal 
function was lower in the diabetes (n=9)  group measured using mitral annular longitudinal 
excursion (MAPSE) and there was greater left atrial size compared to the control group 
(n=7), consistent with other studies (Table 4) (Ha et al., 2007). 
 
Table 4: Standard echocardiographic parameters with mean and SD 
Speckle tracking strain analysis is a more detailed measurement of myocardial function and 
pathology(Gorcsan & Tanaka, 2011)  as it measures myocardial deformation using tissue 
tracking and this is more accurate than looking at simple movement (MAPSE) or volume 
change (ejection fraction) to truly understand the myocardium’s tissue function.  Strain 
analysis was undertaken between the groups to look for subtle left ventricular 
dysfunction/pathology and was assessed in the circumferential, radial and longitudinal 
directions. Global circumferential strain in the diabetes group was nearly 50% lower 
(11.6±6.2) compared to the control group (-20.5±1.9; P=<0.01) and similarly longitudinal 
strain was lower in the diabetes group (-12.7±1.09) compared to the control group (-16.5± 
0.75; P=0.013). As myocardial fibrosis progresses, replacing tissue between myocytes, this 
leads to reduced myocardial deformation which can be measured using strain analysis. In 
our control and diabetes groups we observed longitudinal strain measurements (below -
18%) in the range associated with myocardial fibrosis in diabetes (Ng et al., 2012) and in 
aortic stenosis alone when a normal ejection fraction has been recorded  in patients without 
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diabetes (Weidemann et al., 2009). These figures suggest our diabetes group and control 
group are similarly matched with regards to potential fibrosis. 
 
Ventricular mRNA expression 
Results from the gene expression part of the study are summarized in Table 5, with 
significant increases in the diabetes group for SLC8A1, KCNJ2 and KCNJ5. There was a 
reduction in the diabetes group in the expression of KCNH2 and KCNJ3. 
 
Table 5: mRNA expression with mean and SD. Raw P values and adjusted P values for 
false discovery 
 
Action potential modelling 
Using the mRNA results discussed above, we used the relative percentage difference in 
gene expression to alter current density in the diabetes group and utilising the O’Hara-Rudy 
dynamic model we were able to produce action potentials (AP) for the control and diabetes 
group at both the endocardial and epicardial levels (Table 6).  
 
Figure 1 shows a modelled Aps from the endocardium, A, and epicardium, B. In both 
modelled wall layers, changes in the diabetes groups produced increased amplitudes of the 
action potential, elevation in the plateau phase and prolongation in the AP. We were also 
able to show at the endocardial layer modelled creation of an early after-depolarisation 
(EAD) at the plateau phase, the trigger for many types of ventricular arrhythmias. 
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In Figure 2 panels A (for the endocardium) and B (for the epicardium) the effects of all the 
individual currents are modelled to identify which of the currents are responsible primarily 
for the AP prolongation and EAD generation we have seen at the endocardial layer. Most 
of the currents modelled individually do not have much input into the AP prolongation 
suggested above, apart from INaCa encoded    by    SLC8A1    and    IKr   coded     by 
KCNH2. There was also a very slight acceleration in the final phase of repolarisation, 
creating a steeper rate of descent in the diabetes group which appeared to be created by 
the modelled increase in IK,1. 
 
Discussion 
In this study, we report for the first-time lower left ventricular expression of KCNH2 and in-
creased SLC8A1 in humans with type 2 diabetes and aortic stenosis (compared to non-dia-
betic patients with the same condition) with the corresponding clinical sequelae of prolongation 
of the QT interval. Whilst QT interval elongation in humans with type 2 diabetes (Rutter et al., 
2002) and KCNH2/SLC8a1 mRNA cardiac expression alteration in animal models of diabetes 
(Hattori et al., 2000; Zhang et al., 2007) have been reported previously,  the combination has 
not been reported in humans before. The other novel aspect of our study was the use of a 
control group with a condition other than diabetes that produces LVH and myocardial fibrosis 
(aortic stenosis(Weidemann et al., 2009) and this helps support the theory that gene expres-
sion changes in our diabetes group were as a result of diabetes/hyperglycaemia not just a 
final common downstream pathway linked to fibrosis and LVH.  
 
The major gene expression change found was a marked reduction in ventricular expression 
of ERG mRNA which encodes the pore forming subunit of the IK, r channel, the major outward 
K+ delayed rectifying current with a marked prolongation of the modelled AP. IK, r is a K+ volt-
age gated current which begins to be activated as the membrane potential drops at the end 
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of phase 2, the plateau phase, reaching a current maximum at -40mV during phase 3 allow-
ing for a large outward current. IK, r is at positive voltages in quickly inactivated maintaining 
the AP plateau, but is also quick to recover from inactivation, allowing the generation of the 
large outward current which is largely responsible for phase 3 in humans and limits the AP 
duration(Vandenberg et al., 2012).    
Our AP modelling shows that down-regulation of ERG creates EADs at the endocardial level 
at, which has been reported previously in long QT syndromes with normal cellular cou-
pling(Viswanathan & Rudy, 2000), this being thought to be due to reactivation of  ICa, L, cre-
ated by extension of the plateau phase due to reduced ERG. The endocardium seems to be 
more vulnerable to EADs than the epicardium predominantly as the sharper electrical gradi-
ent between the epicardium and mid-myocardium allows formation of a ‘sink’ for excess cur-
rent in the epicardium reducing EADs in the mid- and epicardial layers(Viswanathan & Rudy, 
2000).  Reduced ERG expression and or ERG blockade clinically in arrhythmogenesis(Gong 
et al., 2007) has been previously reported, particularly in patients with diabetes. (Zhang et 
al., 2006) In previous studies looking at ERG down-regulation, it has been shown that both 
myocardial hypertrophy(Hu et al., 2011) and myocardial fibrosis (Chu et al., 2012) are asso-
ciated with reduced ERG and it was not clear that diabetes had a specific effect on ERG ex-
pression within the myocardium or whether down-regulation of ERG was a function of hyper-
trophy/fibrosis. As discussed above by comparison with a similar control group there seems 
to be a specific effect of diabetes on ERG expression within the myocardium and that this 
may go some way to explaining higher arrhythmia rates in patients with diabetes, particularly 
in the light of the modelled EAD formation and longer QT intervals seen.  
 
As well as reduced ERG expression, we also observed NCX1 over expression which would 
prolong the AP as was shown in our modelling and this with reduced IK, r, leads to EAD gen-
eration at the endocardial level. 
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As well as EAD formation, prolongation of the action potential leads to stimulation of NCX1 
forward mode, and generation of a late transient inward current, ITI, in phase 3 of the action 
potential, which is more likely with a sharper membrane potential drop as we have observed 
in our modelled AP (largely the result of increased IK1) and in patients with hyperglycaemia 
secondary to increased Na+ levels. ITI, can cause delayed after depolarizations (DADs) if the 
current generated is large enough.  
NCX1 expression has been seen to be increased in LV hypertrophy(Menick et al., 2013) and 
by comparing our diabetes group who would be expected to have increased LV mass, with a 
control group with LV hypertrophy (as a result of aortic stenosis) we are able to show sup-
port for the theory that diabetes specifically does seem to be associated with NCX1 overex-
pression. 
The role of NCX1 on the AP has been the subject of much discussion and findings have 
been variable in differing experiments due to the forward and reverse modes of NCX1. It has 
been shown previously in failing canine hearts with high Na+ that NCX 1 acts in the outward 
mode to shorten the AP but in low Na+ states it acts in the inward mode to prolong the 
AP(Armoundas et al., 2003). In similar pathological states with hypertrophy and fibrosis, in-
creased NCX1 has been shown prolong repolarisation at the end of the AP(Wang et al.) and 
over expression of NCX1 in diabetes has been shown in animal models to prolong the AP 
and increase systolic function(LaRocca et al., 2012). There has been conflicting data on 
NCX1 expression in the streptozocin rate model with several papers showing a reduction in 
NCX1 expression(Zhao et al., 2014; Akhtar et al., 2016). In these studies, the studied rats 
were comparatively young with significantly lower body weights and left ventricular function 
and our results may reflect a different diabetes process related to insulin resistance and obe-
sity. 
Contrary to the above changes in KCNH2/SLC8A1, the diabetes group had an up-regulation 
of KCNJ2, the gene responsible for the main component of IK,1 channel, which sets the rest-
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ing membrane potential. Our AP modelling has shown that this probably has only a small ef-
fect on the AP, most obviously in acceleration in phase 3 of repolarisation to give a sharper 
terminal part of the AP and acts to limit the AP duration. The role of IK,1 this setting is difficult 
to be certain of but it is possible that the increase in mRNA may be compensatory in the face 
of the AP prolongation caused by IK, r and NCX1 
The final significant mRNA changes observed were in KCNJ3/5, with reduced expression of 
KCNJ3 in the diabetes group but increased KCNJ5. KCNJ3 codes for a tetrameric, acetyl-
choline activated inward K+ rectifying channel (IK, Ach) that is expressed in the atria and ventri-
cles. Most prior experimental work is mainly on the atrial effects of IK, Ach and we did not in-
corporate this into our biophysical model as the channel is only active with acetylcholine. In 
atrial studies, inhibition of the IK, Ach channel resulted in prolongation of the action potential in 
the atria(Bingen et al., 2013). Whether this effect would be reproduced in the ventricle would 
require physiological testing but seems in keeping with the prolonged AP we have modelled. 
KCNJ5 codes for the remaining two of the four subunits of the IK, Ach channel and has stretch 
related properties and in high stretch situations inhibits channel function (Tamargo et al., 
2004) This upregulation of the stretch sensitive subunits would suggest, that the higher LV 
filling pressures commonly seen in diabetes, may present a mechanism for further IK, Ach 
channel inhibition which would merit further physiological testing.  
 
As with many studies similar to ours, a major limitation is the small sample size and before 
extrapolation to the wide human population with diabetes, larger studies would be needed. 
In our study population, we have had a relatively older group of patients with mean ages 
over 70 years in both groups and  fewer women than men which is an important limitation as 
age (Ocorr et al., 2007; Rabkin, 2014) and gender (Cheng, 2006) are asscoaited with differ-
ences in cardiac repolarisation. A larger study would be needed to assess the importance of 
these factors in the changes we have observed and whether the results could be extrapo-
lated in younger people and by gender specifically. One area of potential limitation is in the 
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medication background of our diabetes group as sulphonylureas have been shown to have 
some effect on the cardiac ATP dependent K+ channel(Aronson et al., 2003) and whilst this 
channel was not assessed in this study, some overlap with the other K+ channel genes stud-
ied here cannot be excluded. Similarly, as metformin has wide ranging effects on growth fac-
tors and anti-fibrotic effect (Bai et al., 2013), some reduction in the gene expression changes 
we may have seen in the study could have occurred. In this study, we used a combination of 
QT prolongation on the ECG with AP modelling and mRNA change to look at the effect of 
diabetes and confirmatory protein measurement of the mRNA results with direct electrophys-
iology measurement of myocytes from the diabetic human hearts would be required for con-
firmation of the effects reported here. Review of the existing literature currently suggests that 
there is reasonable correlation of mRNA with protein measurements(Ellinghaus et al., 2005; 
Brioschi et al., 2009; Ferdous et al., 2016) and with electrophysiological measure-
ments(Howarth et al., 2009) but that correlation is not universal and post-transcriptional 
mechanisms do play an important role in multiple settings(Panguluri et al., 2013), something 
which would need further analysis. 
Conclusion 
Patients with type 2 diabetes have a prolonged QT interval compared to a control population 
with similar levels of LV hypertrophy and that this is associated with gene expression 
changes likely to cause AP prolongation. These findings may partly explain the higher rates 
of ventricular arrhythmias seen in patients with diabetes. 
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Table 2: Patient characteristics. Values are means (SD). Abbreviations: BMI, body mass 
index and HbA1c, glycated haemoglobin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Group Number Caucasian Age (Years) Male Waist (Cm) BMI (kg/m2) HbA1c (mmol/mol-1) 
Control 9 9 78.8 (8.29) 6 35.8 (2.73) 27.8 (2.28) Not recorded 
Diabetes 7 7 74.9 (12.80)  4 39.7 (8.81) 31.2 (6.86)  57.9 (14.57) 
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Table 3: Patient medications. Abbreviations: ACE, angiotensin-converting enzyme and ARB, 
angiotensin receptor blocker 
 
 
 
 
 
 
 
 
 
 
Group Number Beta blocker ACE/ARB Insulin Metformin  Sulphonylureas Statin 
Control 9 3 5 0 0 0 4 
Diabetes 7 3 5 0 4  2 6 
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Table 4: Standard echocardiographic parameters. Values are mean (SD). Abbreviations: LV, 
left ventricle and MAPSE, mitral annular longitudinal excursion. *= statistically significant. 
 
 
 
 
 
Echocardiographic parameter Control 
group 
Diabetes group P value 
Ejection fraction (%) 63.9 (6.53) 58.2 (2.59) 0.09 
LV septal width (cm) 1.6 (0.23) 1.7 (0.44) 0.53 
End systolic volume (mls) 31.6 (14.5) 37.8 (6.22) 0.39 
End diastolic volume (mls) 76.2 (26.5) 89.6 (15.59) 0.33 
MAPSE (cm) 1.6 (0.23) 1.1 (0.20) <0.01* 
Left atrial area (cm2) 20.4 (2.20) 26.9 (5.52)  0.01* 
E/A ratio 0.9 (0.21) 0.9 (0.23) 0.81 
E/e’ lateral 11.2 (3.27) 12.8 (3.42) 0.44 
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Gene  Channel Control mean and 
SD 
Diabetes mean 
and SD 
Raw P-
value 
Adjusted P-
value 
ATP2A2 SERCA2a 4.68x 10-8 
(1.76x 10-7) 
9.61x 10-9 
(1.06x 10-7) 
0.630 0.795 
CACNA1C Cav1.2 0.000302 
(0.0000795) 
 
) 
0.000346 
(0.000192) 
0.551 0.795 
CACNA1D Cav1.3 2.47 x 10-7 
(1.94 x 10-7) 
2.61x 10-7 
(1.53x 10-7) 
0.876 0.876 
HCN1 HCN1 7.1901e-007 
(1.19x 10-6) 
5.48x 10-5 
(0.00000820) 
0.105 0.249 
HCN2 HCN2 0.000119 
(0.0000411) 
6.00x 10-5 
(0.0000454) 
0.0173 0.0546 
HCN4 HCN4 3.27x 10-5 
(0.0000237) 
1.62 x 10-5 
(0.0000164) 
0.139 0.273 
KCNA4 Kv1.4 3.04x 10-5 
(0.0000156) 
2.40x 10-5 
(0.0000162) 
0.438 0.756 
KCNA5 Kv1.5 5.63 x 10-5 
(0.0000432) 
5.11 x 10-5 
(0.0000243) 
0.759 0.811 
KCND2 Kv4.2 2.80x 10-7 
(2.33x 10-7) 
5.86x 10-7 
(3.83 x 10-7) 
0.0679 0.184 
KCND3 Kv4.3 3.23x 10-5 
(0.0000257) 
5.55 x 10-5 
(0.0000343) 
0.143 0.273 
KCNH2 ERG 0.000327 
(0.0000747) 
0.000114 
(0.0000684) 
0.00004 0.000750* 
KCNIP2 KChIP2 0.000109 
(0.0000822) 
0.00014957 
(0.000187) 
0.567 0.795 
KCNJ2 Kir2.1 0.000165 
(0.0000348) 
0.000306 
(0.0000832) 
0.000400 0.00254* 
KCNJ3 Kir3.1 2.06 x 10-5 
(0.00000629) 
2.94 x 10-6 
(0.0000124) 
0.00223 0.0106* 
KCNJ5 Kir3.4 6.02x 10-6 
(1.06x 10-6) 
1.45x 10-5 
(4.96x 10-6) 
0.000190 0.00184* 
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KCNQ1 KvLQT1 0.000136 
(0.0000413) 
0.000128 
(0.0000561) 
0.770 0.811 
RYR2 RYR2 0.00409 
(0.00111) 
0.003601 
(0.00249) 
0.669 0.795 
SCN5A Nav1.5 0.000787 
0.000225) 
0.000952 
(0.000927) 
0.610 0.795 
SLC8A1 NCX1 0.000312 
(0.000179) 
0.00107 
(0.000637) 
0.00394 0.0150* 
 
Table 5: mRNA expression. Values are mean (SD). Raw P values and adjusted P values for 
false discovery. *=Statistically significant. 
 
 
 
Channel Current 
Expression change in the diabetes 
Group 
Nav1.5  INa  +21.08% 
Cav1.2 and 1.3 ICa, L  +14.18% 
Kv1.4, 4.2 and 4.3 ITo  +26.04% 
ERG IK, r -65.24% 
KvLQT1 IK, s -5.38% 
Kir2.1  IK, 1  +85.23% 
NCX1 INaCa  +243.83% 
RYR2 SR Ca2+ release -10.07% 
 
Table 6: Relative mRNA expression changes in the diabetes group used to mathematically 
model the AP 
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Fig 1: Modelled APs at the endocardial level, A and epicardial level, B for the control and 
diabetes groups using relative mRNA expression changes. Run with external stimulus 
pulses at an amplitude of 0.8 nA, duration of 5 ms and frequency of 1 Hz. 
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Fig 2 Individualised APs from the endocardium, A and epicardium, B analysing the effect of 
each current singularly on the AP with control in black and diabetes group in red with scaled 
current change labelled. Run with external stimulus pulses at an amplitude of 0.8 nA, 
duration of 5 ms and frequency of 1 Hz. 
 
